Women With Early-Stage Breast Cancer Report Substantial Treatment-Related Toxicities

Chemotherapy treatment is associated with a higher likelihood of reporting higher toxicity severity.
Chemotherapy treatment is associated with a higher likelihood of reporting higher toxicity severity.

Nearly half of women with early-stage invasive breast cancer report experiencing at least 1 severe or very severe treatment-related toxicity, with approximately 1 in 10 reporting unscheduled clinic visits for toxicity management, a study published in the journal Cancer has shown.1

Although patient-reported toxicities are a factor in determining the quality of the breast cancer treatment experience, most data come from clinical trials and health care claims that may be biased. Therefore, researchers sought to quantify the frequency, severity, and burden of treatment-associated toxicities in patients with early-stage invasive breast cancer using patient surveys.

For the iCanCare study, investigators surveyed 1945 women with early-stage, invasive breast cancer residing in Los Angeles County and Georgia between 2013 and 2014.

Results showed that 45% of patients reported at least 1 toxicity that was severe or very severe and 9% reported unscheduled clinic visits for management of adverse effects. Researchers found that 5% visited an emergency department or hospital to manage toxicities.

The study further demonstrated that receipt of chemotherapy was associated with a 2 times higher likelihood of reporting higher toxicity severity (odds ratio [OR], 2.2; 95% CI, 2.0-2.5).

In addition, receipt of both chemotherapy and radiotherapy (OR, 1.3; 95% CI, 1.0-1.7) and being of Latina ethnicity (OR, 1.3; 95% CI, 1.1-1.5) were each associated with a 30% increased risk of experiencing a toxicity of higher severity.

There was no significant association between receipt of bilateral mastectomy and likelihood of reporting at least 1 severe or very severe toxicity (OR, 1.2; 95% CI, 1.0-1.4).

The findings suggesting that this population reports substantial treatment-associated toxicities and related burden underscore the need for clinicians to collect toxicity data routinely and offer early intervention.

Reference

1. Friese CR, Harrison JM, Janz NK, et al. Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer. 2017 Jan 24. doi: 10.1002/cncr.30547. [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs